Company intelligence / Profile preview

480 Biomedical

Watertown, Massachusetts, United Statesventureradar.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company developed a fully self-expanding, drug-eluting bioresorbable scaffold for vascular disease. Its lead product was being studied in a global clinical trial for superficial femoral artery disease and had advanced to at least early-stage human studies by the mid-to-late 2010s. A second program targeted pulmonary artery stenosis in children with limited treatment options. No recent updates on results or further development are available.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiomaterial-based therapy
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Stanza

Clinical

Indications: Vascular disease

Partnerships

No major pharmaceutical partnerships disclosed publicly.

Beyond the preview

Go deeper on 480 Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 480 Biomedical.

Explore the full profile